[1] Varghese N, Majeed A, Nyalakonda S, et al. Review of related factors for persistent risk of hepatitis B virus-associated hepatocellular carcinoma[J]. Cancers (Basel), 2024,16(4):777.
[2] Ghany M G, Feld J J, Chang K M, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad[J]. Lancet Gastroenterol Hepatol, 2020,5(4):406-417.
[3] Cornberg M, Lok A S, Terrault N A, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-report from the 2019 EASL-AASLD HBV treatment endpoints conference[J]. J Hepatol, 2020,72(3):539-557.
[4] Mücke M M, Backus L I, Mücke V T, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2018,3(3):172-180.
[5] Ahn S H, Marcellin P, Ma X, et al. Correction to: hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: week 120 analysis[J]. Dig Dis Sci, 2019,64(1):285-286.
[6] Choi H, Sonneveld M J, Farag M S, et al. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection[J]. J Viral Hepat, 2021,28(12):1729-1737.
[7] 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 中华肝脏病杂志, 2023,31(4):355-384. |
